SSO Bio announced the completion of nearly RMB300 million round D financing

December 8, 2020, following the completion of nearly 600 million yuan of C-round financing in the first half of the year, precision medicine leader So Yuan Bio announced that it had just completed a D-round financing of nearly 300 million yuan. The current round of financing by the FUND Qide Fund and PCCW Capital co-led investment, China Resources Pharmaceutical Industry Investment Fund, Paradise Silicon Valley, Anda Biopharmaceutical Fund and Hangshi Capital Management to join the new shareholder lineup, the existing shareholders Xianxian Capital, Houxin Jian Investment and Zhejiang Commercial Finance to participate.Soyuan Bio is a new type of international enterprise that develops a new class of new drugs in a unique and fast and effective mode. Soryuan Bio currently has seven products (DB102 - DB108) developed in the field of oncology and psychotic diseases, all of which are the world's first in Class or a class of new drugs. The International Multi-Center Clinical Phase III Trial (ENGINE Study) of DB102 (enzastaurin) for first-line treatment of diffuse large B-cell lymphoma (DLBCL) has been completed in all patient groups. Db102's International Multi-Center Clinical Phase III Trial (ENGAGE Study) for the treatment of newly diagnosed cerebroglioblastoma (GBM) has also been approved by the U.S. Drug Administration (FDA) and China's National Drug Administration (NMPA) and has been fully launched in the United States and China. In July, based on early clinical data, DB102 showed excellent results in DGM1-positive and high-dose DB102 patients, and the FDA granted DB102 fast track eligibility for first-line treatment. (Shell Society)